Detection of cobalamin deficiency using the urinary methylmalonic acid test by gas chromatography mass spectrometry

In their recent paper Chanarin *et al*¹ state that urinary methylmalonic acid (MMA) concentrations are not an early sign for the detection of cobalamin (Cbl) deficiency. They base their opinion on a study that used gas chromatography as a means to quantify urinary MMA. Methodology using gas chromatography only lacks the specificity and sensitivity to accurately differentiate slightly increased concentrations of urinary MMA from normal amounts of urinary MMA.

Measurement of urinary MMA by gas chromatography mass spectrometry (GC/MS) is a highly sensitive and specific test for detecting Cbl deficiency.²⁻⁵ Norman *et al*² identified 54 consecutive inpatients with Cbl deficiency using the urinary MMA assay by GC/MS and 20% had a normal hematocrit at diagnosis. In a prospective clinical evaluation of the urinary MMA test by GC/MS Matchar *et al*³ studied inpatients with obvious Cbl deficiency and Cbl deficient patients. They determined the assay to have a sensitivity of 100% and a specificity of 99%. Specker *et al*⁴ used the urinary MMA assay by GC/MS to detect Cbl deficiency in a non-anaemic strict vegetarian population. More recently, the high sensitivity of the assay was demonstrated by identifying Cbl deficient non-anaemic persons over the age of 65 of whom 40% had serum Cbl concentrations in the normal range.⁵

False negative results have not been reported for the urinary MMA assay by GC/MS.²⁻⁵ It should be noted, however, that a "gold standard" test for Cbl deficiency does not exist because neither the Schilling test nor the serum total Cbl assay is a functional test. The serum MMA assay lacks specificity because the test can give falsely high values in patients with renal insufficiency or intravascular volume depletion. The urinary MMA test by GC/MS is normalised to urinary creatinine, and falsely high urinary MMA concentrations have not been reported in patients with renal insufficiency.⁵

Thus the urinary MMA test by GC/MS detects early Cbl deficiency, can routinely identify non-anaemic Cbl deficiency and is perhaps the "gold standard" for identifying true functional Cbl tissue deficiency.

ERIC J NORMAN
Monarch Foundation,
400 Oak Street Cincinnati,
Ohio 45219

Acanthamoeba keratitis

The case report on *Acanthamoeba* keratitis¹ and subsequent response² require elaboration.

Acanthamoeba is a ubiquitous free-living protozoan which occurs in a wide range of environmental niches including domestic tap water. Inhalation of the organism or its penetration into open wounds can lead to development of granulomatous amoebic encephalitis, a chronic central nervous system infection with a prolonged clinical course which in some circumstances may prove fatal.³ *Acanthamoeba* has been cultured from the nasopharynx of normal, healthy subjects and there are a significant number of people with antibody against the organism.

Acanthamoeba keratitis was first recorded in 1974. A large number of cases have been reported subsequently, perhaps as a consequence of increased recognition of the condition. As was highlighted previously,¹ however, awareness of the role of these amoebae in clinical diagnosis and practice is limited. Earlier reports suggested an association between keratitis and trauma with a foreign body contaminated with *Acanthamoeba*. Currently, most presentations are from contact lens wearers, increasingly with so-called "disposable" contact lenses, where these have been immersed in inappropriate disinfecting systems.⁴ For example, commercially available chlorine systems will fail to kill *Acanthamoeba* cysts⁵ if the latter are present in the reusable contact lens storage case.⁶ The condition is more frequently detected in young immunocompetent persons who wear contact lenses for cosmetic purposes, and who have poor compliance with contact lens disinfection regimens. In one study, about 7% of contact lens cases contained viable cysts of *Acanthamoeba*.⁷ The incidence of *Acanthamoeba* keratitis in contact lens wearers in the USA is of the order of 1:250 000.⁸

Recognition of early ocular disease in contact lens wearers due to *Acanthamoeba* is all important. It initially presents as a punctate or dendriform epitheliopathy and may proceed to stromal invasion. *Acanthamoeba* keratitis is therefore most often misdiagnosed initially as herpes simplex keratitis and treated as such with antiviral agents and possibly corticosteroids. If such treatment fails the next diagnosis is often of fungal infection. Definitive diagnosis of *Acanthamoeba* keratitis from superficial corneal scrapings may prove inconclusive, because the organism can be present deeper within the stroma. In such circumstances corneal biopsy extending deeper into the stromal abscess is required; excised tissue should then be subjected to light and transmission electron microscope examination and cultured for the presence of viable amoebae.

For routine culture, a non-nutrient agar (1.5%), prepared at least 24 hours in advance, is seeded with heat-killed *Escherichia coli* or *Klebsiella aeruginosa*. Corneal scraping or tissue is gently spread across the central area of two separate plates, one to be incubated at 25°C and the other at 33°C. If the specimen is to be forwarded to a reference laboratory, it should be placed in sterile isotonic saline and kept at room temperature before despatch. Often clinical specimens which contain *Acanthamoeba*, and amoebae which have been subjected to topical chemotherapy or

corticosteroids, require supplements to promote growth and development of the amoebae in culture. If necessary, various biochemical or molecular biological methods can be used to provide unequivocal speciation and strain identification of the pathogenic *Acanthamoeba*.

Medical treatment with combined topical treatment comprising propamidine isethionate plus neomycin at an early stage can be successful.⁹ If unrecognised, the infection progresses to a ring abscess when medical treatment is often unsuccessful and a corneal graft, including on occasion, a second graft, is required. Anti-acanthamoebic drugs at this stage may result in emergence of temperature sensitive and drug resistant strains of the organism.¹⁰ Sensitivity testing of cultured clinical isolates must therefore be performed.

J HAY
DV SEAL
Acanthamoeba Research Laboratory,
Glasgow Royal Infirmary,
Wolfson Centre, Level 5 31 Taylor Street,
Glasgow G4 0NA

CM KIRKNESS
Tennent Institute of Ophthalmology,
Western Infirmary,
Glasgow G11 6WT

- 1 Anderson D, Soo SS, Towler H. *Acanthamoeba* keratitis: experience in a non-specialist laboratory. *J Clin Pathol* 1991;44:699.
- 2 Casemore DP, Warhurst DC. *Acanthamoeba* keratitis. *J Clin Pathol* 1992;45:367.
- 3 Martinez AJ. *Free-living amoebae: Natural history, prevention, diagnosis, pathology, and treatment of disease*. Boca Raton, Florida: CRC Press, Inc, 1985.
- 4 Seal DV, Hay J. Contact lens disinfection and *Acanthamoeba*: problems and practicalities. *Pharmacol J* 1992;248:717-9.
- 5 Seal DV, Hay J, Devonshire P, Kirkness CM. *Acanthamoeba* and contact lens disinfection: should chlorine be discontinued? *Br J Ophthalmol* (in press).
- 6 Seal DV, Stapleton F, Dart J. Possible environmental sources of *Acanthamoeba* spp in contact lens wearers. *Br J Ophthalmol* 1992;76:424-7.
- 7 Larkin DFP, Kilvington S, Easty DL. Contamination of contact lens storage cases by *Acanthamoeba* and bacteria. *Br J Ophthalmol* 1990;74:133-5.
- 8 Stehr-Green JK, Bailey TM, Visvesvara GS. The epidemiology of *Acanthamoeba* keratitis in the United States. *Am J Ophthalmol* 1989;107:331-6.
- 9 Wright P, Warhurst D, Jones BJ. *Acanthamoeba* keratitis successfully treated medically. *Br J Ophthalmol* 1985;69:778-82.
- 10 Ficker L, Seal D, Warhurst D, Wright P. *Acanthamoeba* keratitis—resistance to medical therapy. *Eye* 1990;4:835-8.

Factors affecting the maintenance dose of warfarin

James *et al*¹ have confirmed the observations of others that elderly patients require less warfarin than younger patients to achieve the same intensity of anticoagulation.²⁻⁴ They suggest that the age dependency of dose should perhaps be taken into account in judging initial dose. We have already studied this question⁴ and have demonstrated that if a flexible induction dose regimen such as that of Fennerty *et al*⁵ is used elderly patients can safely start on the same initial dose as other patients. Should a fixed dosage schedule be used this might not necessarily be so.

BJ BAIN
University of London,
St Mary's Hospital Medical School,
Department of Haematology, Norfolk Place,
Paddington, London W2 1PG

- 1 Chanarin I, Deacon R, Lumb M, Perry J. Cobalamin and folate: Recent developments. *J Clin Pathol* 1992;45:277-83.
- 2 Norman EJ. Gas chromatography mass spectrometry screening of urinary methylmalonic acid: early detection of vitamin B₁₂ (cobalamin) deficiency to prevent permanent neurologic disability. *GC/MS News* 1984;12:120-9.
- 3 Matchar DB, Feussner JR, Millington DS, Wilkinson RH Jr, Watson DJ, Gale D. Isotope-dilution assay for urinary methylmalonic acid in the diagnosis of vitamin B₁₂ deficiency. A prospective clinical evaluation. *Ann Int Med* 1987;106:707-10.
- 4 Specker BL, Miller D, Norman EJ, Greene H, Hayes KC. Increased urinary methylmalonic acid excretion in breast fed infants of vegetarian mothers and an identification of an acceptable dietary source of vitamin B₁₂. *Am J Clin Nutr* 1988;47:89-92.
- 5 Norman EJ, Morrison JA. Screening elderly populations for cobalamin (vitamin B₁₂) deficiency using the urinary methylmalonic acid assay by gas chromatography mass spectrometry. *Am J Med*.